Press Release: AFFiRiS : AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology

AFFiRiS: DGAP-News: AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference

AFFiRiS: AFFiRiS : announces publication in Movement Disorders Journal of positive clinical results of a Phase 1 trial in early Multiple System Atrophy

AFFiRiS: Adamas presents new post-hoc data analysis for GOCOVRI in Parkinson's disease patients with dyskinesia at the 2020 Movement Disorder Society Virtual Congress

AFFiRiS: AFFiRiS : The Lancet Neurology publishes positive results of AFFiRiS' Phase 1 trial with PD01A in Parkinson's disease patients

AFFiRiS: AFFiRiS : Neurobiology of Disease publishes encouraging preclinical results of AFFiRiS' antibody mAB C6-17 to treat Huntington's disease

AFFiRiS: World Parkinson's Day: AFFiRiS developing PD01 to treat Parkinson's disease, a major unmet medical need